Latest / CME Outfitters Medical Education

Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team
The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes and apply emerging evidence to routine practice. With antibody-drug conjugates (ADCs) transforming the treatment landscape, today’s oncology and pathology teams need practical guidance that connects diagnostic precision with therapeutic decision-making to improve patient outcomes.
In the first activity of this…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.